visibl rais pt
tafamidi mortal benefit assum
tafamidi ttr-cm data present esc follow
conf call expect relative-risk reduct cv mortal
post sig reduct cv-relat hospit assum under-
diagnos pt global us penetr
annual us cost yield us sale tafamidi
stringent cv-endpt/or admin set apart alnylam/ioni asset
expect visibl rise project asset
maintain hold/rais pt ep support
dcf
host tafamidi attr-act data call monday et dial-
password esc
tafamidi lucr orphan drug bullish pipelin
tafamidi data present european societi cardiolog
esc munich-germani local estimate follow
analyst call expect tafamidi post rel risk reduct
composit endpoint all-caus mortal along reduct cv
relat hospit result rais tafamidi sale
four-year result attr-act studi
patient transthyretin cardiomyopathi ttr -cm assum global
preval ttr-cm pt low diagnosi rate contribut slow
ramp assum penetr us time annual
treatment cost repres us sale
global pfe near-term pipelin oppi support growth
innov medicin pim busi assum approv
high valu oppi exhibit four opportun
life-cycle management exist brand xeljanz ulcer coliti us/eu global
market xtandi non-metastat colorect cancer bavencio/inlyta combo
rcc remain oncolog prioriti review vaccin
rais pt ep support
dcf downsid pt could come clinic regulatori commerci
tr target
tafamidi mortal benefit ttr-cm assum
announc top-lin result march see note titl tafamidi meglumin meet
primari endpoint orphan ttr cardiomyopathi diseas tafamidi show statist
signific clinic meaning reduct combin all-caus mortal frequenc cv-
relat hospit vs placebo robust endpoint high barrier pfe phase attr-act
studi global trial evalu oral dose tafamidi patient hereditari
 wild-typ form ttr-cm major patient wt promin patient
popul tafamidi met primari endpoint studi show statist signific reduct
month compar placebo composit endpoint measur all-caus mortal
frequenc cv-relat hospit character tafamidi primari endpoint result
clinic meaning find notabl elect pursu cv-event relat endpoint
meant trial set high bar tafamidi prove efficaci pfe choic
stringent endpoint also meant requir four year conduct studi initi dec
safeti tafamidi well-toler ttr-cm patient present data
esc expect simultan publish result new england journal medicin
fda grant tafamidi track breakthrough therapi design expect submit
regulatori file support approval/launch remind tafamidi approv
vyndaqel transthyretin famili amyloid polyneuropathi ttr-fap eu
ttr-cm awareness/increas diagnosi adopt driver
ttr-cm rare diseas lead progress heart failur accord research publish
amyloid journal averag life expect ttr-cm patient approxim year
differ type ttr-cm includ hereditari form ttr famili amyloid cardiomyopathi ttr-
fac ii non-hereditari form wild-typ ttr cardiomyopathi accord research publish
journal commun hospit intern medicin perspect awar ttr-cm among
cardiologist low diseas often misdiagnos hypertens heart failur estim
diagnos ttr-cm patient world-wide less overal patient
diagnos moreov diagnosi process ttr-cm complex scintigraphi
non-invas diagnosi technolog avail ttr-cm adopt fairli limit clinic
practic henc need invest build market tafamidi execut diseas
awar program cater physician patient drive adopt non-invas imag
technolog assum ttr-cm patient diagnos estim global preval pool
tafamidi estim assum penetr us annual price
repres us sale global
competit target differ use less stringent endpt
competit front ioni rate alnylam anli rate pursu inject
oligonucleotid treatment hereditari attr amyloidosi hattr although hattr also
caus mutat ttr gene similar ttr-cm two differ relat indic
result mostli cardiac symptom hattr result mostli neurolog symptom alnylam rna
interfer rnai therapeut onpattro patrisiran approv fda august
ioni tegsedi inotersen inject pdufa date set treatment hattr
score mni primari endpoint conduct tafamidi pivot studi includ
stringent cv-outcom endpt believ tafamidi benefit/risk profil along conveni
oral dose differenti onpattro/tegsedi
oncolog commercial/regulatori catalyst focu
near-term catalyst includ us launch xtandi nmcrpc fda approv snda juli
ibranc pallet studi ibranc letrozol neoadjuv bc expect read fall
bavencio multipl upcom read-out ovarian renal gastric lung
bladder ovarian fda grant prioriti review pfe talazoparib parp file
embraca data gbrca breast cancer pdufa goal dec also anticip fda
action prioriti review lorlatinib nsclc august ema/jpmda
decis late dacomitinib fda/ema review egfr nsclc sept
pdufa prioriti review pfe glasdegib prioriti review treatment aml dec
pdufa expect manufactur disrupt sip busi resolv start
begin co-promot cologuard non-invas stool dna screen test colorect
page
cancer conjunct rate follow pfe/astella
rate protocol amend xtandi arch metastat hormon sensit embark non-
metastat hormon sensit trial revis acceler primari complet date late
page
exhibit manag expect potenti blockbust
page
page
midpointsuntrust estimatesconsensu statement guidancerevenu yoy weaken eur cni jpygross sg anticip spend late-stag pipelineoper incomenot providednot providednot providednot incom beyond incom adjust providednot providednot providednot epsnot providednot providednot providednot flow operationsnot providednot providednot providednot dilut relat stock-comp share yellow indic updat pfizer inc
exhibit estim strh vs consensu
page
page
datecompanyproductev categoryev sub-typecommentsfal trial pallet studi patient neoadjuv settingaug actionpdufa ask nsclc base result part hear best idea increas biosimilar adoptionsept actionpdufa egfr nsclc base archer studi gildfilgotinib jak clinic data releasefinch ra tortuga ankylos spondyl oct entryftf anda filer hikma could potenti launch gener abirateron end late tripletsclinicaltri read-outresult io triplet studi avelumab earli jpmda actionema jpmda action alk nsclc base result earli actionexpect ema action egfr nsclc base archer data accept apr actionema action psoriat arthriti javelin second line ovariandec actionfda action talazoparib parp gbrca breast cancer base embraca data prioriti dec actionfda action glasdegib acut myeloid leukemia base bright data prioriti review late trial arch studi metastat hormon sensit prostat cancer llytanezumabclinicaldata releasephas trial durat osteoarthr oa hip llytanezumabclinicaldata releasephas long-term safeti trial osteoarthr oa hip llytanezumabclinicaldata releasephas tango trial chronic lower back painmarch deadlin releas interchang guidelin releasetop-lin data vaso-occlus crisi hospit subject sickl cell read-outtop-lin expect javelin renal bavencio inlyta actionema action talazoparib parp gbrca breast cancer base read-outpivot javelin lung studi first line non-smal cell lung cancer read-outpivot javelin read-outpivot javelin read-outpivot javelin read-outpivot javelin io chemo advanc malign pfizer inc
exhibit product strh vs consensu
page
innov in-lin productslyrica ih in-lin pfizer inc
exhibit product strh vs consensu
page
essenti in-lin legaci establish product steril inject pharmaceut sip eh in-lin pfizer inc
exhibit product strh vs consensu
page
innov pipelin productsalli revenu avelumab strh- ertugliflozin strh- ih pipelin pfizer inc
exhibit product strh vs consensu
page
revenueconsum inc
page
 /min incom outstand ep analysi gross oper pre-tax tax net chang good gross oper pre-tax net incom share metricspric pfizer inc
page
 short-term receiv expens current properti plant loan sharehold equityst debt current portion lt tax current discontinu busi -- -- -- -- -- -- -- -- -- -- -- -- -- total current benefit benefit tax stock carri paid-in comprehens sharehold equiti attribut non-control sharehold liabil inc
exhibit statement flow
page
net compens sale equiti invest -- -- -- -- -- -- -- -- -- -- -- -- -- loss gain sale impair work short-term short-term sale long-term redempt long-term sale sale busi -- -- -- -- -- -- -- -- -- -- -- -- -- invest issuanc long-term long-term short-term short-term option common discontinu oper -- -- -- -- -- -- -- -- -- -- -- -- -- effect exchang begin end pfizer inc
global biopharmaceut compani focus drug discoveri develop
commerci pfe total sale sale evenli divid
us ex-u market pfe innov health ih brand busi account
total net sale ih hous intern medicin vaccin oncolog inflamm immunolog
sale brand ih busi compris lyrica neuropath pain fibromyalgia
pneumococc vaccin sever oncolog asset ibranc xtandi sutent inlyta
xalkori pfe franchis compris enbrel xeljanz eucrisa
pfe establish health eh gener busi account sale legaci
establish product account eh sale steril inject pharmaceut peri-
loe product infus system divest center-on biosimilar repres
 respect eh busi compris erstwhil blockbust product
lipitor premarin norvasc epipen celebrex xalatan viagra zithromax effexor xanax zoloft
relpax etc robust biosimilar pipelin account sale sourc
hospira acquisit biosimilar molecul clinic develop
rate hold base long-term growth outlook sales/ep cagr lowest amongst
peer group pfe innov health busi crucial top-lin growth next five
year look weather combin across busi given expect
challeng us volum /gross-to-net sale trend matur product recent forthcom
loss exclus eh busi lyrica eu enbrel eu/jp zyvox us relpax us/
eu tygacil us/eu viagra rapamun eu pfe top-lin growth hing limit number
intern develop brand growth driver across intern medicin lyrica us chantix us
oncolog ibranc xtandi xeljanz/xr eucrisa franchis number ih franchis
face competit headwind includ prevnar lyrica gener competit eu loe enbrel ex-
us biosimilar competit oncolog competit xalkori roche/novartis/oth inlyta/
sutent renal cell carcinoma opdivo advers impact perform
oncolog late immuno-oncolog io market bavencio fifth entrant
crowd io market bullish doublet triplet io combo therapi although toxic
cost consider temper enthusiasm competit space rise
verzenio abemaciclib kisqali launch place downward pressur ibranc trajectori
addit pfe eh segment see global price competit especi us gener
price declin mid-to-high teen rate attempt mitig risk aggress
price increas biosimilar portfolio asset goal five biosimilar
regulatori file note biolog eros legal hurdl high bar biosimilar
interchang stifl growth
need biosimilar portfolio along steril inject minim declin
legaci eh product peri-lo product account essenti health sale result
busi pressur done tuck-in acquisit hospira anacor mediv
howev expect bolt-on large-scal transform deal improv long-
term growth rate re-consid split ih eh busi abandon
septemb
valuat risk
arriv target price assum stock trade ep
believ below-averag multipl compar peer group warrant due pfe anem growth
outlook higher concentr sale gener eh account sale view
stock range-bound sinc manag demonstr lack urgenc time
pfe dividend yield aggress share repurchas add floor stock view
dcf analysi yield intrins valu per share
page
risk thesi includ increas competit key growth product ibranc
xalkori inlyta sutent xtandi xeljanz bavencio price pressures/high discount rebat
demand payer govern greater expect gener price compress
legaci eh product peri-lo addit risk overpay larg
biopharma acquisit convers also note sourc posit risk could includ earlier
expect transform drive sharehold return better expect perform
growth asset instanc eliqui posit blood thin market could add signific
upsid pfe allianc revenu xtandi could receiv boost sale perform
non-metastat segment prostat cancer market
compani mention note
rate
astella rate
ioni rate
alnylam anli rate
john bori herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
